Nykode Therapeutics AS (FRA:5VB) Moat Score: 4/10 (As of Jun. 28, 2026)


FRA:5VB Nykode Therapeutics AS FRA:5VB
37 GF Score
Price €0.25
GF Value €0.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Moat Score?

Nykode Therapeutics AS FRA:5VB -0.61% 37 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates FRA:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.49 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,402 Biotechnology companies, Nykode Therapeutics AS ranks better than 88.8% on this metric.

Nykode Therapeutics AS has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Nykode Therapeutics AS has Narrow Moat: Nykode Therapeutics AS has a discernible moat due to its valuable intellectual property and ongoing R&D efforts. However, it operates in a highly competitive biotech sector with significant risks and lacks strong brand strength or market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Nykode Therapeutics AS might have Narrow Moat - Discernible but modest moat.

Nykode Therapeutics AS  (FRA:5VB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Nykode Therapeutics AS Moat Score Related Terms

FRA:5VB vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Nykode Therapeutics AS's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Moat Score distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Moat Score falls into.


FRA:5VB
37GF Score
Nykode Therapeutics AS FRA:5VB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Nykode Therapeutics AS (FRA:5VB) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Nykode Therapeutics AS ranks #157 out of 1402 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Nykode Therapeutics AS's Moat Score too high?
Nykode Therapeutics AS's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Nykode Therapeutics AS's value of 4 is 100% above this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #157 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #157 out of 1402 companies for Moat Score. This places Nykode Therapeutics AS in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Nykode Therapeutics AS's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.25 — trading 50% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.25 is trading 50% below its estimated GF Value™ of €0.49. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for FRA:5VB:

  • Moat Score: 4
  • GF Value™: €0.49 vs. price of €0.25 (50% below fair value)
  • GF Score™: 37/100 with 2 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1402)

No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score

Get the complete analysis for FRA:5VB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.49
GF Value